Drug intelligence / Profile preview

IA-101

Development stage: Preclinical
Lead developer: ImmuneAGE Bio
Modality: Small Molecules
Administration: Oral

Overview

IA-101 is an oral small molecule immune booster developed by ImmuneAGE Bio to address immune senescence in elderly populations. The compound was identified through the company's proprietary discovery platform, which utilizes large-scale ex vivo combinatorial drug screening to target hematopoietic stem cells (HSCs) in the bone marrow. By rejuvenating HSC function, IA-101 aims to enhance the immune system's ability to combat respiratory infections and improve the efficacy of vaccine responses in older adults. As of 2024, the program is undergoing IND-enabling studies.

Other names: IA-101IA101IA 101

Beyond the preview

Go deeper on IA-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IA-101.

Explore the full profile